risankizumab
Selected indexed studies
- Risankizumab for Ulcerative Colitis: Two Randomized Clinical Trials. (JAMA, 2024) [PMID:39037800]
- Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease. (N Engl J Med, 2024) [PMID:39018531]
- Risankizumab. (, 2012) [PMID:34251778]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Risankizumab for Ulcerative Colitis: Two Randomized Clinical Trials. (2024) pubmed
- Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease. (2024) pubmed
- Risankizumab. (2012) pubmed
- Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. (2022) pubmed
- Risankizumab: Mechanism of action, clinical and translational science. (2024) pubmed
- Risankizumab. (2006) pubmed
- Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial. (2022) pubmed
- Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. (2018) pubmed
- Risankizumab for the treatment of psoriasis. (2019) pubmed
- Risankizumab: First Global Approval. (2019) pubmed